News >

ODAC Recommends Approval of Gemtuzumab Ozogamicin for Newly-Diagnosed AML

Jason Harris
Published: Tuesday, Jul 11, 2017

David Harrington, PhD

David Harrington, PhD

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 6-1 in favor of approving gemtuzumab ozogamicin (Mylotarg) in combination with daunorubicin and cytarabine for the treatment of patients with newly-diagnosed CD33-positive acute myeloid leukemia (AML).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication